QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:OCUP

Ocuphire Pharma (OCUP) Stock Price, News & Analysis

$2.01
-0.01 (-0.50%)
(As of 05:22 PM ET)
Today's Range
$1.99
$2.03
50-Day Range
$1.89
$2.79
52-Week Range
$1.85
$6.60
Volume
121,779 shs
Average Volume
197,588 shs
Market Capitalization
$49.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.00

Ocuphire Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
845.3% Upside
$19.00 Price Target
Short Interest
Bearish
6.65% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.80mentions of Ocuphire Pharma in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$74,100 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.53) to ($0.42) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.91 out of 5 stars

Medical Sector

411th out of 938 stocks

Pharmaceutical Preparations Industry

189th out of 425 stocks

OCUP stock logo

About Ocuphire Pharma Stock (NASDAQ:OCUP)

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate for dim light or night vision disturbances; and for pharmacologically induced mydriasis and presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. The company is headquartered in Farmington Hills, Michigan.

OCUP Stock Price History

OCUP Stock News Headlines

Altcoin FRENZY Alert…
Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days…
Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
Ocuphire Pharma Inc (OCUP)
Ocuphire Pharma Names Joseph Schachle COO
See More Headlines
Receive OCUP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocuphire Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/08/2024
Today
3/28/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:OCUP
Employees
9
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$19.00
High Stock Price Target
$20.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+850.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-9,990,000.00
Pretax Margin
-52.36%

Debt

Sales & Book Value

Annual Sales
$19.05 million
Book Value
$2.20 per share

Miscellaneous

Free Float
22,654,000
Market Cap
$49.62 million
Optionable
Optionable
Beta
0.36
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Richard J. Rodgers M.B.A. (Age 57)
    Interim President & Director
    Comp: $62k
  • Mr. Bernhard Hoffmann M.B.A. (Age 68)
    Senior Vice President of Corporate Development & Operations and Secretary
    Comp: $348.96k
  • Ms. Amy Zaremba Rabourn C.P.A. (Age 43)
    MAcc, Senior Vice President of Finance
    Comp: $384.52k
  • Mr. George Magrath M.B.A.
    M.D., M.S., CEO & Director
  • Mr. Nirav Suresh Jhaveri C.F.A.
    Chief Financial Officer
  • Mr. Joseph K. Schachle MBA (Age 59)
    Chief Operating Officer
  • Dr. Ashwath Jayagopal Ph.D.
    Chief Scientific & Development Officer
  • Dr. Daniela C. Oniciu Ph.D.
    Global Head of R&D, Chemistry and Product Development
  • Dr. Mitchell Brigell Ph.D.
    Head of Clinical Development & Strategy
  • Mr. Chris Ernst
    Global Head of QA & Manufacturing

OCUP Stock Analysis - Frequently Asked Questions

Should I buy or sell Ocuphire Pharma stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ocuphire Pharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OCUP shares.
View OCUP analyst ratings
or view top-rated stocks.

What is Ocuphire Pharma's stock price target for 2024?

3 brokers have issued 12 month price objectives for Ocuphire Pharma's stock. Their OCUP share price targets range from $17.00 to $20.00. On average, they anticipate the company's share price to reach $19.00 in the next twelve months. This suggests a possible upside of 845.3% from the stock's current price.
View analysts price targets for OCUP
or view top-rated stocks among Wall Street analysts.

How have OCUP shares performed in 2024?

Ocuphire Pharma's stock was trading at $3.01 on January 1st, 2024. Since then, OCUP stock has decreased by 33.2% and is now trading at $2.01.
View the best growth stocks for 2024 here
.

When is Ocuphire Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our OCUP earnings forecast
.

How were Ocuphire Pharma's earnings last quarter?

Ocuphire Pharma, Inc. (NASDAQ:OCUP) issued its quarterly earnings data on Friday, March, 8th. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by $0.14. The business earned $1.69 million during the quarter, compared to the consensus estimate of $3.47 million. Ocuphire Pharma had a negative trailing twelve-month return on equity of 22.30% and a negative net margin of 52.42%.

Who are Ocuphire Pharma's major shareholders?

Ocuphire Pharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.10%), Vanguard Group Inc. (4.10%), Richmond Brothers Inc. (1.12%), Bridgeway Capital Management LLC (0.77%), Northern Trust Corp (0.23%) and Victory Capital Management Inc. (0.21%). Insiders that own company stock include George Magrath, James S J Manuso, Jay Pepose, Joseph K Schachle, Mina Sooch and Nirav S Jhaveri.
View institutional ownership trends
.

How do I buy shares of Ocuphire Pharma?

Shares of OCUP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OCUP) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners